ciprofloxacin has been researched along with B cepacia Infection in 12 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We evaluated the activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime by determination of the MICs for 66 genotypically characterized Burkholderia cepacia isolates obtained from the sputum of cystic fibrosis patients." | 7.70 | Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. ( Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999) |
| " Porton outbred mice and Syrian hamsters were given 40 mg/kg of either doxycycline or ciprofloxacin twice daily by sc injection according to one of three regimens: dosing starting 48 h before challenge and continuing for 5 days postchallenge; 5 days' therapy starting immediately after challenge; 5 days' therapy starting 24 h after challenge." | 5.31 | Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. ( Bell, DL; Eley, SM; Ellis, J; Green, M; Kenny, DJ; Russell, P; Titball, RW, 2000) |
| "We evaluated the activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime by determination of the MICs for 66 genotypically characterized Burkholderia cepacia isolates obtained from the sputum of cystic fibrosis patients." | 3.70 | Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis. ( Bingen, E; Bonacorsi, S; Fitoussi, F; Lhopital, S, 1999) |
| " Porton outbred mice and Syrian hamsters were given 40 mg/kg of either doxycycline or ciprofloxacin twice daily by sc injection according to one of three regimens: dosing starting 48 h before challenge and continuing for 5 days postchallenge; 5 days' therapy starting immediately after challenge; 5 days' therapy starting 24 h after challenge." | 1.31 | Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders. ( Bell, DL; Eley, SM; Ellis, J; Green, M; Kenny, DJ; Russell, P; Titball, RW, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 6 (50.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhou, J | 1 |
| Chen, Y | 1 |
| Tabibi, S | 1 |
| Alba, L | 1 |
| Garber, E | 1 |
| Saiman, L | 1 |
| Stundick, MV | 1 |
| Albrecht, MT | 1 |
| Houchens, CR | 1 |
| Smith, AP | 1 |
| Dreier, TM | 1 |
| Larsen, JC | 1 |
| Ferreira, AS | 1 |
| Silva, IN | 1 |
| Fernandes, F | 1 |
| Pilkington, R | 1 |
| Callaghan, M | 1 |
| McClean, S | 1 |
| Moreira, LM | 1 |
| Van Acker, H | 1 |
| Gielis, J | 1 |
| Acke, M | 1 |
| Cools, F | 1 |
| Cos, P | 1 |
| Coenye, T | 1 |
| Elborn, JS | 1 |
| Hodson, M | 1 |
| Bertram, C | 1 |
| Pope, CF | 1 |
| Gillespie, SH | 1 |
| Moore, JE | 1 |
| McHugh, TD | 1 |
| Lieberman, TD | 1 |
| Michel, JB | 1 |
| Aingaran, M | 1 |
| Potter-Bynoe, G | 1 |
| Roux, D | 1 |
| Davis, MR | 1 |
| Skurnik, D | 1 |
| Leiby, N | 1 |
| LiPuma, JJ | 1 |
| Goldberg, JB | 1 |
| McAdam, AJ | 1 |
| Priebe, GP | 1 |
| Kishony, R | 1 |
| Manno, G | 1 |
| Ugolotti, E | 1 |
| Belli, ML | 1 |
| Fenu, ML | 1 |
| Romano, L | 1 |
| Cruciani, M | 1 |
| Magalhães, M | 1 |
| de Britto, MC | 1 |
| Vandamme, P | 1 |
| Otağ, F | 1 |
| Ersöz, G | 1 |
| Salcioğlu, M | 1 |
| Bal, C | 1 |
| Schneider, I | 1 |
| Bauernfeind, A | 1 |
| Bonacorsi, S | 1 |
| Fitoussi, F | 1 |
| Lhopital, S | 1 |
| Bingen, E | 1 |
| Russell, P | 1 |
| Eley, SM | 1 |
| Ellis, J | 1 |
| Green, M | 1 |
| Bell, DL | 1 |
| Kenny, DJ | 1 |
| Titball, RW | 1 |
1 review available for ciprofloxacin and B cepacia Infection
| Article | Year |
|---|---|
Animal models for Francisella tularensis and Burkholderia species: scientific and regulatory gaps toward approval of antibiotics under the FDA Animal Rule.
Topics: Animals; Anti-Bacterial Agents; Burkholderia; Burkholderia Infections; Ciprofloxacin; Disease Models | 2013 |
11 other studies available for ciprofloxacin and B cepacia Infection
| Article | Year |
|---|---|
Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; Burkholderia cepacia complex; Burkholderia Infections; Cystic Fibrosis; Drug | 2007 |
The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line.
Topics: Albumins; Anti-Bacterial Agents; Bacterial Adhesion; Burkholderia cepacia complex; Burkholderia Infe | 2015 |
The Role of Reactive Oxygen Species in Antibiotic-Induced Cell Death in Burkholderia cepacia Complex Bacteria.
Topics: Anti-Bacterial Agents; Biofilms; Burkholderia cepacia complex; Burkholderia Infections; Cell Death; | 2016 |
Implementation of European standards of care for cystic fibrosis--control and treatment of infection.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Bacterial Infections; Burkholderia cepacia | 2009 |
Approaches to measure the fitness of Burkholderia cepacia complex isolates.
Topics: Adult; Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; Biofilms; Burkholderia ce | 2010 |
Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes.
Topics: Adaptation, Biological; Anti-Bacterial Agents; Bacteremia; Burkholderia; Burkholderia Infections; Ci | 2011 |
Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.
Topics: Bacteriological Techniques; Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Chi-Square D | 2003 |
Burkholderia cepacia genomovar III and Burkholderia vietnamiensis double infection in a cystic fibrosis child.
Topics: Amikacin; Anti-Infective Agents; Burkholderia; Burkholderia cepacia complex; Burkholderia Infections | 2002 |
Nosocomial bloodstream infections with Burkholderia stabilis.
Topics: Adolescent; Adult; Aged; Bacteremia; Bacterial Typing Techniques; Burkholderia; Burkholderia Infecti | 2005 |
Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.
Topics: Burkholderia cepacia; Burkholderia Infections; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Drug Syn | 1999 |
Comparison of efficacy of ciprofloxacin and doxycycline against experimental melioidosis and glanders.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia Infections; Burkholderia pseudom | 2000 |